Skip to main content

Table 2 Comparison of immune responses after tetanus-diphtheria (Td) vaccine with or without concomitant 13-valent pneumococcal conjugate vaccine (PCV13)

From: Immunogenicity and safety of a tetanus-diphtheria vaccine and a 13-valent pneumococcal conjugate vaccine after concomitant vaccination in ≥ 50-year-old adults

Antigen

Parameters of immunogenicity

Group 1 (N = 151)

Group 3 (N = 148)

p-value

Tetanus

GMT fold increase (95% CI)

8.6 (6.6–11.2)

8.5 (6.5–11.2)

0.47

GMT (95% CI)

 Pre-vaccination

0.05 (0.04–0.06)

0.07 (0.06–0.08)

0.01

 1 month post-vaccination

0.43 (0.34–0.54)

0.59 (0.46–0.75)

0.06

Pre-vaccination antibody titer

 ≥ 0.1 U/mL, No. (%)

28 (18.5)

31 (20.9)

0.66

Post-vaccination antibody titer

 ≥ 0.1 U/mL, No. (%)

128 (84.8)

130 (87.8)

0.50

 ≥ 0.5 U/mL, No. (%)

40 (26.5)

75 (50.7)

< 0.01

Diphtheria

GMT fold increase (95% CI)

13.0 (9.1–18.5)

7.9 (5.4–11.7)

0.14

GMT (95% CI)

 Pre-vaccination

0.07 (0.07–0.08)

0.08 (0.07–0.10)

0.36

 1 month post-vaccination

0.96 (0.70–1.34)

0.67 (0.50–0.90)

0.10

Pre-vaccination antibody titer

 ≥ 0.1 U/mL, No. (%)

54 (35.8)

48 (32.4)

0.71

Post-vaccination antibody titer

 ≥ 0.1 U/mL, No. (%)

120 (79.5)

120 (81.1)

0.77

 ≥ 0.5 U/mL, No. (%)

96 (63.6)

91 (61.5)

0.72

  1. Abbreviations: CI Confidence interval, GMT Geometric mean titer
  2. Group 1: PCV13 + Td vaccine administered concomitantly
  3. Group 3: Td administered alone